Author： Bryskier A.
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.6, Iss.10, 1997-10, pp. : 1479-1500
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Codrugs comprise a b-lactam-fluoroquinolone antibacterial hybrid. These new agents have been developed with the aim of enhancing the antibacterial spectrum of current therapies, overcoming intrinsic and acquired resistance, and diminishing severe side-effects. A few compounds, including Ro 23-9424, have entered Phase I clinical trials. Furthermore, a series of oral codrugs have been synthesised, although clear oral bioavailability has not yet been demonstrated. New drugs are urgently needed to treat Gram-positive resistant bacteria.
Related content
Access to resources
Recommend
Antibacterial Activity of Lipophilic Fluoroquinolone Derivatives
Medicinal Chemistry, Vol. 5, Iss. 5, 2009-09 ,pp. :
By Cabrera Perez M.A. Gonzalez Daz H. Fernandez Teruel C. Pla-Delfina J.M. Bermejo Sanz M.
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 53, Iss. 3, 2002-05 ,pp. :